AstraZeneca stock trades 20.60 percent below its yearly high

Published on 09/29/2026 at 07:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock reflects 9 percent H1 revenue growth and a 12 percent rise in core EPS. JPMorgan kept its Overweight rating and GBp 16,000.00 target.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor — AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

AstraZeneca stock (ISIN GB0009895292) stood at GBp 12,492.00 on the London Stock Exchange on September 28, 2026, placing it 20.60 percent below its 52-week high of GBp 15,732.00. The latest investor debate combines strong first-half earnings with a pipeline that must offset patent pressure.

First half delivers double digit EPS growth

According to StockQuay, AstraZeneca reported USD 30.672 billion in total revenue for H1 2026, up 9 percent year over year and 6 percent at constant exchange rates. Core EPS increased 12 percent to USD 5.21, while reported EPS rose 4 percent to USD 3.60.

The company said its Oncology business grew 15 percent at constant exchange rates during H1 2026, helping offset pressure from generic competition affecting Farxiga and Brilinta. AstraZeneca's results calendar identifies the H1 and Q2 2026 announcement as a July 27, 2026 release, and the company reaffirmed full-year guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth in the period, according to AstraZeneca.

Pipeline value meets execution risk

The current catalyst is clinical rather than purely financial. In a September 8, 2026 filing, StockTitan reported that Imfinzi combined with Imdelltra produced statistically significant improvements in overall survival and progression-free survival in the DeLLphi-305 Phase III trial. The study enrolled 563 patients, but the data still require presentation to regulators before any label expansion.

J.P. Morgan kept AstraZeneca at Overweight with a GBp 16,000.00 price target on September 16, 2026, according to finanzen.net. The target is 28.08 percent above the September 28 share price, making the bank's view dependent on late-stage pipeline delivery and continued commercial growth.

Stock remains below yearly peak

AstraZeneca shares were last quoted at GBp 12,492.00 on the LSE on September 28, 2026, down 0.48 percent for the session. The same quotation showed a 52-week range of GBp 9,892.00 to GBp 15,732.00 and volume of 1,543,696 shares, leaving the price 26.28 percent above its yearly low.